Compare Cytokinetics Inc (CYTK) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Yum! Brands, Inc. — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Yum! Brands, Inc. trades at $144.82 (market cap $39.02B). The key difference: Yum! Brands, Inc. is far larger — about 4.5× Cytokinetics Inc's market cap, and Yum! Brands, Inc. pays a 2.1% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Yum! Brands, Inc. for 132 Days on average.
| CYTK | YUM | |
|---|---|---|
Market Cap | $8.62B | $39.02B |
Volume | 2,594,626 | 2,597,636 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $168.16 |
52-Week Low | $54.76 | $135.77 |
Typical Hold Time | 19 Days | 132 Days |
Enterprise Value | $8.72B | $50.63B |
Dividend Yield | — | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
YUM trades at $143.00, up 1.89% over 24 hours, with a bullish technical signal and strong support at $141. Revenue has grown from $6.8B in 2022 to $8.2B in 2025, with net income reaching $1.56B. Recent news highlights KFC's new Open House restaurant concept in Texas, testing expanded menus and customer experiences.
The outlook remains positive with a consensus price target of $170.44, though risks include high debt levels and competitive pressures. Earnings have beaten expectations in two of the last three quarters, with Q3 2026 results pending. Analyst sentiment is mixed with 39.22% buy ratings, 54.9% hold, and 5.88% sell.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
